Key facts
- Notable investors include Sofinnova Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for BioClec
- ·The full record, as it builds
Funding rounds
No funding rounds for BioClec are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioClec
Operator of a biotechnology company intended to develop precision therapies for Alzheimer's disease. The company is focused on the discovery and development of neuroimmunology therapies targeting microglia, the brain's immune cells, to treat Alzheimer's disease and dementia, enabling doctors to get access to novel drugs in areas of unmet neurodegenerative disease treatment.
- Sector
- Healthcare
- HQ
- Milan, Italy
- Website
- bioclec.com/
- Ownership
- Privately Held (backing)
BioClec doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioClec shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioClec in its N-PORT filings yet. We sweep new filings monthly.